Abbott Q3 net earnings drop 44% year over year to $920 million
ABT•Abbott's third-quarter 2026 net earnings fell 44% year over year to $920 million, while net sales rose 15% to $13.01 billion. FDA approvals expanded its portfolio with the Libre Duo glucose-ketone sensor and TactiFlex Duo catheter.
1. Quarterly results
Abbott's third-quarter 2026 net earnings fell 44% year over year to $920 million. Net sales increased 15% to $13.01 billion.
2. FDA approvals
FDA approvals expanded Abbott's portfolio with the Libre Duo glucose-ketone sensor and TactiFlex Duo catheter for treating atrial fibrillation.
